论文部分内容阅读
[目的]观察蒲地蓝消炎口服液+三联疗法根除幽门螺杆菌的临床疗效。[方法]110例幽门螺杆菌阳性患者随机分为治疗组56例和对照组54例,对照组采用三联疗法治疗,治疗组加用蒲地蓝消炎口服液治疗,其疗程均为14d,停药4周后,对2组患者进行对照观察,判定疗效。[结果]幽门螺杆菌根除率治疗组为78.6%,对照组为66.7%,治疗组疗效明显优于对照组(P<0.05)。临床总有效率,治疗组明显高于对照组。不良反应2组间差异无统计学意义。[结论]蒲地蓝消炎口服液+三联疗法可明显提高幽门螺杆菌根除率,临床疗效显著,不良反应少,值得临床应用推广。
[Objective] To observe the clinical efficacy of Po Di Lan Xiaoyan oral liquid + triple therapy in the eradication of Helicobacter pylori. [Method] One hundred and ten Helicobacter pylori positive patients were randomly divided into treatment group (56 cases) and control group (54 cases). The control group was treated with triple therapy. The treatment group was treated with Puda Lan anti-inflammatory oral liquid for 14 days. Weeks later, the two groups of patients were controlled observation to determine the efficacy. [Results] The cure rate of Helicobacter pylori in treatment group was 78.6%, while that in control group was 66.7%. The curative effect of treatment group was better than that of control group (P <0.05). The total effective rate of the treatment group was significantly higher than that of the control group. Adverse reactions between the two groups showed no significant difference. [Conclusion] PuDiLan antiphlogistic oral liquid + triple therapy can significantly improve the eradication rate of Helicobacter pylori. The clinical curative effect is remarkable and the adverse reactions are few, so it is worth to be popularized in clinical application.